Plasmodium Falciparum Malaria — ICC-1132 - Candidate Vaccine Against P Falciparum Malaria
Citation(s)
Phase I Trial of ICC-1132, a Candidate Vaccine Against Plasmodium Falciparum Malaria Based on a Viral-like Particle Comprising Recombinant Hepatitis B Core Antigen and Circumsporozoite Epitopes, to Assess Vaccine Safety and Immunogenicity in Healthy Adult Volunteers